期刊文献+

普拉曲沙有关物质的合成

Synthesis of related substances of pralatrexate
原文传递
导出
摘要 目的 加强普拉曲沙的质量控制,合成4个普拉曲沙有关物质,为其质量研究提供对照品。方法 以4-{2-[(2,4-二氨基蝶啶-6-基)甲基]-1-甲氧基-1-氧代-4-戊炔-2-基}苯甲酸甲酯为起始原料,经水解、脱羧、酰化反应,再经水解反应,得到杂质A;以4-{1-[(2,4-二氨基蝶啶-6-基)基]-4-戊炔-2-基}苯甲酸为起始原料,分别与D-谷氨酸二甲酯盐酸盐、L-谷氨酸-1-甲酯盐酸盐、L-谷氨酸-5-甲酯盐酸盐进行酰化缩合,再分别水解或经柱色谱分离,得到杂质B、C及D。结果与结论合成的4种普拉曲沙有关物质的结构均经HR-MS、1H-NMR、13C-NMR谱确证,杂质总收率为8.5%~60.9%,纯度为94.37%~98.33%。4种杂质可用于普拉曲沙原料药的质量控制和质量研究。 Four related substances of pralatrexate were synthesized to strengthen the quality control of pralatrexate and to provide reference for its quality research.Using methyl 4-{2-[(2,4-diaminopteridin-6-yl)methyl]-1-methoxy-1-oxopent-4-yn-2-yl}benzoate as the starting material, impurity A was obtained by hydrolysis, decarboxylation, acylation, and finally hydrolysis.Using 4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoic acid as the starting material, highly pure impurities B,C and D were obtained by acylate and condensation with D-glutamic acid dimethyl carbonate, L-glutamic acid-1-methyl carbonate, L-glutamic acid-5-methyl carbonate, and then hydrolysis or direct column chromatography, respectively.The structures of four impurities were confirmed by HR-MS,1H-NMR and 13C-NMR,which can be used in the quality control of pralatrexate.The syntheses of impurities C and D were reported for the first time and have certain application value.
作者 郑直 郑鹛 胡志 ZHENG Zhi;ZHENG Mei;HU Zhi(Hangzhou East China Pharmaceutical Group New Drug Research Institute Co.,Ltd.,Hangzhou 310011,China;Hangzhou Bangshun Pharmaceutical Co.,Ltd.,Hangzhou 311113,China;Shanghai Puruida Biomedical Technology Co.,Ltd.,Shanghai 201399,China)
出处 《中国药物化学杂志》 CAS 2023年第5期356-361,共6页 Chinese Journal of Medicinal Chemistry
关键词 普拉曲沙 有关物质 对映异构体 pralatrexate related substance enantiomer
  • 相关文献

参考文献3

二级参考文献14

  • 1RILEY K. FDA approves first drug for treatment of peripheral T- cell lymphoma [ J ]. Mul Cell Pharmacol,2009,1 (4) : 230 - 232.
  • 2FOLOTYN [ EB/OL ]. [ 2010 - 05 ]. http ://www. folotyn. com/ sites/default/files/pdf/Folotyn_PI. pdf.
  • 3IZBICKA E,DIAZ A,STREEPER R, et al. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers [ J ]. Cancer Che- mother Pharmacol,2009,64 ( 5 ) :993 - 999.
  • 4MARNEROS AG, GROSSMAN ME, SILVERS DN,et al. Prala-trexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin ero- sions[ J ]. Blood ,2009,113 (25) :6338 - 6341.
  • 5LEITENBERGER JJ, BERTHELOT CN, POLDER KD, et al. CD4^+ CD56^+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate [ J ]. J Am Acad Dermatol, 2008,58 ( 3 ) : 480 - 484.
  • 6DAMAJ B. In vitro and in vivo effects of pralatrexate (PDX) on the survival and growth of the A549 non-small cell lung cancer cell line. [ EB/OL]. [ 2008 -04 - 12 ]. http ://www. aaermeet- ing abstracts. org/cgi/content/meeting_abstract/200S/I _Annual_ Meeting/2298.
  • 7MARCHI E,PAOLUZZI L,SCOTTO L,et al. Pralatrexate is syn- ergistic with the proteasome inhibitor Bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies [ J ]. Clin Cancer Res ,2010,16( 14 ) :3648 - 3658.
  • 8TONER LE, VRHOVAC R, SMITH EA, et al. The schedule-de- pendent effects of the novel antifolate pralatrexate and gemcit- abine are superior to methotrexate and cytarabine in models of hu- man Non-Hodgkin's lymphoma [ J ]. Clin Cancer Res, 2006, 12 (3) :924 -932.
  • 9KRUG LM,HEELAN RT,KRIS MG. Phase II trial of pralatrexate (10-propargyl-10-deaz- aamino pterin, PDX) in patients with unresectable malignant pleural mesothelioma[ J ]. J Thorac Oncol , 2007,2(4) :317 - 320.
  • 10AZZOLI CG,KRUG L,MILLER V, et al. Phase I study of the antifolate pralatrexate given with vitamin B12 and folic acid sup- plementation in patients ( pts ) with advanced non-small cell lung cancer (NSCLC) [ J]. J Clin Oncol, 2007,25 (18S) : 13006.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部